Jazz Pharmaceuticals’ (JAZZ) Overweight Rating Reiterated at Piper Sandler

Jazz Pharmaceuticals (NASDAQ:JAZZ)‘s stock had its “overweight” rating reiterated by equities researchers at Piper Sandler in a report issued on Thursday,Benzinga reports. They currently have a $163.00 target price on the specialty pharmaceutical company’s stock, down from their previous target price of $166.00. Piper Sandler’s target price points to a potential upside of 36.70% from the company’s previous close.

Other research analysts have also issued reports about the stock. Needham & Company LLC reiterated a “buy” rating and issued a $207.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, November 7th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $140.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Royal Bank of Canada increased their price target on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 23rd. HC Wainwright reiterated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, August 1st. Finally, TD Cowen decreased their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $175.33.

Jazz Pharmaceuticals Stock Up 2.1 %

Shares of NASDAQ JAZZ opened at $119.24 on Thursday. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The firm has a fifty day simple moving average of $112.64 and a two-hundred day simple moving average of $110.45. The firm has a market capitalization of $7.21 billion, a PE ratio of 16.79, a price-to-earnings-growth ratio of 0.98 and a beta of 0.57. Jazz Pharmaceuticals has a 12 month low of $99.06 and a 12 month high of $134.17.

Insider Activity

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $110.84, for a total value of $110,840.00. Following the transaction, the chief executive officer now owns 428,976 shares of the company’s stock, valued at approximately $47,547,699.84. This trade represents a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Neena M. Patil sold 3,700 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the transaction, the executive vice president now directly owns 33,048 shares in the company, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,110 shares of company stock valued at $720,160 in the last 90 days. 4.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Versant Capital Management Inc increased its position in Jazz Pharmaceuticals by 13,450.0% in the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 269 shares during the last quarter. Itau Unibanco Holding S.A. bought a new position in shares of Jazz Pharmaceuticals in the second quarter worth about $29,000. EverSource Wealth Advisors LLC grew its holdings in shares of Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 97 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after purchasing an additional 116 shares during the last quarter. Finally, Gladius Capital Management LP bought a new position in shares of Jazz Pharmaceuticals in the second quarter worth about $33,000. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.